The AI-Powered Path to Revolutionising Rare Disease Research

Revolutionising Rare Disease Research: The AI-Powered Path to Inclusivity and Efficiency

In the intricate landscape of rare disease clinical trials and orphan drug development, Artificial Intelligence (AI) has the potential to accelerate the development process and the delivery of new treatments to patients by facilitating collaboration between Patient Advocacy Groups (PAGs) and researchers. To explore this further, Pharma IQ spoke to Dr. Harsha Rajasimha, the visionary founder and chairman of IndoUSRare, who is at the forefront of this transformative approach. His journey, which is fuelled by both personal experience and professional expertise, exemplifies the potential of AI to revolutionise the field, making it more inclusive, efficient, and globally accessible.

Understanding the Potential Benefits of Utilising AI in Rare Disease Clinical Trials

The challenges in rare disease research are manifold. With orphan drug development typically extending over 15 years, from first patent filing to product launch, and diagnoses often delayed by decades, the need for innovation is clear. Patient advocacy groups (PAGs) have long been essential in bridging the gap between researchers and the rare disease community. However, despite their critical role, the collaboration between PAGs and researchers often encounters hurdles, underscoring the necessity for new methodologies to foster trust and streamline processes.

AI-driven clinical tools emerge as a solution, offering omnichannel communication and automated workflows to enhance the collaboration between researchers and PAGs. These tools not only facilitate better coordination but also promise to tackle the logistical and representation challenges plaguing the field. Dr. Rajasimha, Founder & Chairman, IndoUSRare, underscored the importance of leveraging AI to address these issues, particularly in enhancing ethnic representation and inclusivity in clinical trials. As he explained, with only 25% of participants being non-white and half of the rare disease patients being children, the need for a more accessible and equitable approach is undeniable.

The IndoUSRare Initiative

Under Dr. Rajasimha's leadership, IndoUSRare has become a pivotal force in rare disease advocacy. An independent non-profit organisation focused on helping patients with rare diseases of Indian origin in the USA, India, and globally, IndoUSRare exists to build collaboration, accelerate research, and develop diagnostics and therapeutics through education, advocacy, research & grants.

The Crucial Role of Patient Advocacy Groups and AI

PAGs have long been instrumental in connecting researchers with a broader patient base, playing a vital role in patient recruitment and the design of patient-friendly protocols. Dr. Rajasimha highlighted how AI can streamline these collaborations, making them more efficient and effective. Through patient registries, AI technologies facilitate the organisation and analysis of vast amounts of data on disease progression, treatment outcomes, and patient experiences. This data is critical for understanding the natural history of rare diseases and designing targeted interventions.

Overcoming the Diversity Gap in Clinical Trials

When it comes to the persistent challenge, posed by the significant diversity gap in rare disease research and clinical trial participation, Dr. Rajasimha explains that existing data sets, primarily composed of Caucasian populations, limit the generalisability and effectiveness of research findings. AI offers a pathway to more inclusive research by enabling the analysis of diverse data sets and facilitating language translation and clinical trial accessibility, thereby broadening participant recruitment across different ethnic and demographic groups.

Streamlining Clinical Trials through Unified Systems

The fragmented nature of clinical trial management often leads to inefficiencies and barriers to effective collaboration, and without unified data, it isn’t possible to effectively implement and leverage the benefits of AI. Traditionally, a single clinical trial might be managed using up to 30 different tools, each with its separate log-in, meaning that the trial data is siloed and you can’t effectively implement AI or Machine Learning (ML). There might be a tool for patient recruitment built on AI, but that does not necessarily benefit patient engagement, where patients may drop out due to poor enrollment engagement, or data management, where clinical data is being entered and there are inconsistencies and errors. A single, unified AI-driven clinical trial management system can address these challenges. By integrating various tools and processes into a single system, AI simplifies the clinical trial process, from patient recruitment to data management, enhancing the scalability and efficiency of rare disease research. Dr. Rajasimha shared that this is the reason that alongside the IndoUSRare initiative, he has utilised his professional expertise to establish Jeeva Clinical Trials, which is focused on ensuring trials are universally accessible to patients, and on building a unified software system with a single log-in.

Navigating Logistical Challenges with AI

Logistical issues, such as the geographical dispersion of patients and the need for specialised care, particularly for paediatric patients, pose significant hurdles to clinical trial participation. Dr. Rajasimha explains that the use of AI-driven telemedicine, remote monitoring, and wearable technologies can mitigate these challenges, but this requires a shift from traditional clinical trial models to a more patient-centric approach. Decentralised Trials (DCTs) and Direct-to-Patient (DTP) logistics are essential and the barriers preventing widespread adoption of these need to be overcome, as such innovations enable patients to participate in trials with minimal disruption to their lives, thereby improving recruitment and retention rates.

Fostering Global Collaboration

IndoUSRare's efforts in building collaborative bridges between the United States and India underscore the importance of global collaboration in rare disease research. AI technologies play a crucial role in facilitating cross-border partnerships, offering platforms for data sharing, communication, and joint analysis. Dr. Rajasimha explained that AI can bring together diverse stakeholders, including PAGs, researchers, and biopharmaceutical companies, to accelerate the development of orphan drugs and therapies.

The Path Forward

AI/ML has the potential to transform rare disease clinical trials and orphan drug development. By enhancing collaboration, broadening diversity, streamlining processes, and overcoming logistical hurdles, AI/ML paves the way for more efficient, inclusive, and effective research. As the pharmaceutical and healthcare industries continue to embrace these technologies, the promise of accelerated progress in rare disease treatment becomes increasingly tangible, marking a new era of hope and innovation for patients.

For more information on the work of IndoUSRare, visit https://www.indousrare.org/ 

For more information on the implementation of AI in drug discovery and development, join the Pharma IQ community https://www.pharma-iq.com/